Humana Inc. (NYSE:HUM) Shares Purchased by Meeder Asset Management Inc.

Key Points

• Meeder Asset Management Inc. significantly increased its stake in Humana Inc. by 19,108.3% in the first quarter, now holding 6,915 shares valued at approximately $1.83 million.
• Investor activity has intensified around Humana, with several firms like Applied Finance Capital Management and Deseret Mutual Benefit Administrators also increasing their holdings.
• Analyst consensus rates Humana with a "Hold" rating, and recent price targets vary, with estimates ranging from $260 to $348.

Meeder Asset Management Inc. raised its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 19,108.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,915 shares of the insurance provider's stock after purchasing an additional 6,879 shares during the period. Meeder Asset Management Inc.'s holdings in Humana were worth $1,830,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Allstate Corp purchased a new stake in Humana during the 4th quarter valued at about $905,000. Deutsche Bank AG boosted its position in Humana by 18.2% in the fourth quarter. Deutsche Bank AG now owns 631,371 shares of the insurance provider's stock valued at $160,185,000 after buying an additional 97,071 shares during the last quarter. Janney Montgomery Scott LLC acquired a new position in Humana in the 1st quarter worth approximately $1,309,000. Fred Alger Management LLC purchased a new position in Humana during the 4th quarter worth approximately $451,000. Finally, Clearline Capital LP acquired a new stake in Humana during the 4th quarter valued at approximately $1,102,000. Hedge funds and other institutional investors own 92.38% of the company's stock.

Humana Trading Down 1.4%

HUM traded down $3.44 on Friday, hitting $246.43. The company had a trading volume of 1,003,634 shares, compared to its average volume of 1,745,809. The company's fifty day moving average price is $234.64 and its 200 day moving average price is $255.48. Humana Inc. has a 1 year low of $206.87 and a 1 year high of $382.72. The company has a current ratio of 1.95, a quick ratio of 1.91 and a debt-to-equity ratio of 0.69. The firm has a market cap of $29.74 billion, a P/E ratio of 18.94, a PEG ratio of 1.72 and a beta of 0.44.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). The business had revenue of $32.39 billion for the quarter, compared to analysts' expectations of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%. The firm's revenue for the quarter was up 9.6% on a year-over-year basis. During the same quarter last year, the company earned $6.96 earnings per share. As a group, equities analysts expect that Humana Inc. will post 16.47 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on HUM. Guggenheim initiated coverage on shares of Humana in a research report on Wednesday, April 9th. They set a "buy" rating and a $326.00 target price for the company. Bank of America reduced their price objective on Humana from $320.00 to $260.00 and set a "neutral" rating for the company in a research note on Tuesday, June 17th. Truist Financial dropped their target price on Humana from $280.00 to $260.00 and set a "hold" rating on the stock in a report on Wednesday, July 16th. Raymond James Financial upgraded Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price target for the company in a research report on Thursday, May 1st. Finally, Oppenheimer upped their price objective on Humana from $300.00 to $310.00 and gave the stock an "outperform" rating in a research report on Thursday, May 1st. Sixteen equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $281.62.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.